（记者 曾健辉） 每经AI快讯，泰林生物2月6日晚间发布公告称，浙江泰林生物技术股份有限公司全资子公司浙江泰林 生命科学有限公司、浙江泰林医学工程有限公司于近期共取得了3项专利证书。专利名称分别为"一种耐 压气体微生物采集器""水中两虫及浮游生物一体化自动成像及识别分析装置"等。 每经头条（nbdtoutiao）——基金经理个人炒股合法吗？我们调查了多家头部公募，答案出人意料 ...

证券代码：300813 证券简称：泰林生物 公告编号：2026-002 浙江泰林生物技术股份有限公司 关于取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰 林生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司 （以下简称"泰林医学工程"）于近期共取得了 3 项专利证书，具体情况如下： 2026 年 2 月 6 日 | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种耐压气体微生物采集器 | 实用 | 2025201624754 | 2026/1/30 | 泰林生命科学 | | 2 | 水中两虫及浮游生物一体化自动 成像及识别分析装置 | 实用 | 2025201637148 | 2026/2/3 | 泰林生命科学 | | 3 | 一种放射性药品自动检测设备 | 实用 | 2025201666812 | 2026/2/3 | 泰林医学工程 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

证券代码：300813 证券简称：泰林生物 公告编号：2026-001 上述专利的取得不会对公司及全资子公司泰林生命科学、泰林医学工程近期 生产经营产生重大影响，但有利于公司及全资子公司泰林生命科学、泰林医学工 程进一步完善知识产权保护体系，发挥自主知识产权优势，并形成持续创新机制， 保持技术领先地位，提升核心竞争力。 特此公告。 浙江泰林生物技术股份有限公司董事会 2026 年 1 月 13 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰 林生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司 （以下简称"泰林医学工程"）于近期共取得了 3 项专利证书，具体情况如下： | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种微生物检测过滤装置 | 实用 | 2024232919786 | 2026/1/2 | 泰林生命科学 | | 2 | 用于放射性药品 ...

浙江泰林生物技术股份有限公司 关于取得专利证书及计算机软件著作权登记证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司（以下简称"公司"）全资子公司浙江泰林 生命科学有限公司（以下简称"泰林生命科学"）、浙江泰林医学工程有限公司（以 下简称"泰林医学工程"）、浙江泰林分析仪器有限公司（以下简称"泰林分析仪 器"）于近期共取得了 3 项专利证书以及 1 项计算机软件著作权登记证书，具体 情况如下： 证券代码：300813 证券简称：泰林生物 公告编号：2025-086 浙江泰林生物技术股份有限公司董事会 2025 年 12 月 31 日 上述专利证书的取得不会对公司及全资子公司泰林医学工程、泰林生命科学 近期生产经营产生重大影响，但有利于公司及全资子公司泰林医学工程、泰林生 命科学进一步完善知识产权保护体系，发挥自主知识产权优势，并形成持续创新 机制，保持技术领先地位，提升核心竞争力。 上述计算机软件著作权登记证书的取得不会对公司及全资子公司泰林分析 仪器近期生产经营产生重大影响，但在一定程度上有利于发挥公司及全资子公司 泰 ...

Group 1 - The core event was the provincial industrial new product acceptance review meeting for the MD500 microbial rapid detection analyzer held on October 29, 2025, at Zhejiang Tailin Analytical Instrument Co., Ltd. [4][14] - The review committee consisted of several industry experts, and the meeting was hosted by staff from the Hangzhou Economic and Information Technology Bureau [4][14] - The company's core project team presented the product's technological innovations and core advantages, receiving high praise from the expert panel for its outstanding performance [4][14] Group 2 - The MD500 microbial rapid detection analyzer addresses pain points in microbial detection for industries such as pharmaceuticals, semiconductors, and food, successfully overcoming the 72-hour delay of traditional culture methods [7][17] - The product utilizes innovative laser-induced fluorescence and Mie scattering technology, enabling real-time and precise monitoring of microorganisms in water, meeting stringent requirements of the Chinese Pharmacopoeia and GMP standards [7][17] - As a national high-tech enterprise, Tailin Analytical is committed to driving industrial upgrades through technological innovation and plans to increase R&D investment for developing advanced detection equipment [9][19]

Core Insights - The 2025 Second Forum on High-Quality Water Production and Supply was successfully held in Jinan from December 8-10, featuring participation from various prestigious institutions and companies in the water sector [1][10] Group 1: Event Overview - The forum included case sharing on high-quality water production, supply, disinfection, and water safety monitoring from institutions like Harbin Institute of Technology, Tongji University, Tsinghua University, and others [1][10] - The event showcased the collaboration between TaiLin and Jiangsu Hongzhong Baide Biotechnology Co., focusing on accelerating smart water quality monitoring [3][12] Group 2: Product Showcase - TaiLin exhibited a range of products including intelligent analyzers for algae and two worms, automated detection systems, and microbiological testing equipment, emphasizing accurate and efficient water quality detection [3][12] - The product lineup included enzyme substrate method microbiological automatic counting instruments and sampling bottles, aimed at enhancing water quality analysis technology [3][12] Group 3: Technological Insights - Manager Ling provided an in-depth analysis of the core value of smart monitoring technology in ensuring drinking water safety, presenting TaiLin's innovative water ecological detection product system and its applications [6][17] - The company has developed a comprehensive product matrix covering online monitoring, portable detection, and emergency response, creating a full-chain solution from source warning to incident response [6][17] Group 4: Presentation Highlights - During a special report session, Manager Ling delivered a presentation titled "Smart Monitoring Empowers Drinking Water Safety: TaiLin Water Ecological Detection Products and Full-Scene Applications" [7][15] - The presentation highlighted how TaiLin utilizes enzyme substrate methods and intelligent analyzers to transition drinking water safety management from passive response to proactive warning, demonstrating significant improvements in monitoring efficiency and cost reduction [9][19]

浙江泰林生物技术股份有限公司 关于取得专利证书的公告 证券代码：300813 证券简称：泰林生物 公告编号：2025-085 特此公告。 浙江泰林生物技术股份有限公司董事会 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 12 月 5 日 | 序号 | 专利名称 | 专利类型 | 申请号 | 授权公告日 | 专利权人 | | --- | --- | --- | --- | --- | --- | | 1 | 一种电动安瓿瓶开瓶装置 | 发明 | 2023111810779 | 2025/11/28 | 泰林生命科学 | | 2 | 一种气路底板充气装置充气的方 | 发明 | 2022106176736 | 2025/11/28 | 泰林分析仪器 | | | 法 | | | | | 上述专利的取得不会对公司及全资子公司泰林生命科学、泰林分析仪器近期 生产经营产生重大影响，但有利于公司及全资子公司泰林生命科学、泰林分析仪 器进一步完善知识产权保护体系，发挥自主知识产权优势，并形成持续创新机制， 保持技术领先地位，提升核心竞争力。 浙江泰林生物技术股份 ...

Core Viewpoint - TaiLin Bio's stock price has shown volatility, with a year-to-date increase of 56.12%, but a recent decline over the past 20 and 60 days, indicating potential market fluctuations and investor sentiment changes [1]. Financial Performance - For the period from January to September 2025, TaiLin Bio reported revenue of 213 million yuan, a year-on-year decrease of 12.08%, while net profit attributable to shareholders was 14.72 million yuan, reflecting a year-on-year increase of 30.13% [2]. - Cumulative cash dividends since the company's A-share listing amount to 117 million yuan, with 60.1 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 13.61% to 9,437, while the average circulating shares per person increased by 15.76% to 8,058 shares [2]. - Notably, the fund "Noan Multi-Strategy Mixed A" has exited the list of the top ten circulating shareholders [3]. Market Activity - On November 28, TaiLin Bio's stock price fell by 2.02% to 26.65 yuan per share, with a trading volume of 19.08 million yuan and a turnover rate of 0.93%, resulting in a total market capitalization of 3.23 billion yuan [1]. - The net inflow of main funds was 1.1 million yuan, with large orders accounting for 15.25% of purchases and 9.49% of sales [1].

Core Viewpoint - Tailin Bio (300813) responded to investor inquiries on the interactive platform, indicating that specific shareholder information can be found in the company's disclosed periodic reports [1] Group 1 - The company provided a response regarding shareholder information [1]